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Inflammatory CNS Demyelination: Histopathologic
Correlation with In Vivo Quantitative
Proton MR Spectroscopy
Andreas Bitsch, Harald Bruhn, Vassilios Vougioukas, Argyris Stringaris, Hans Lassmann,
Jens Frahm, and Wolfgang Bru¨ck
BACKGROUND AND PURPOSE: The mechanisms behind the demyelination that is char-
acteristic of multiple sclerosis (MS) are still poorly understood. The purpose of this study was
to compare immunopathologic findings in demyelinating lesions of three patients with in vivo
assessments obtained by quantitative proton MR spectroscopy (MRS).
METHODS: Between four and seven stereotactic needle brain biopsies were performed in
three young adults with diagnostically equivocal findings for MS. Axonal density, gliosis, blood
brain–barrier breakdown, and demyelinating activity of lesions were determined. Combined
MR/MRS studies were performed (T1-weighted fast low-angle shot and single-voxel stimulated-
echo acquisition mode), and absolute metabolite levels were obtained with a user-independent
fitting routine. Metabolite control values were obtained from a group of age-matched healthy
volunteers (n540, age range, 20–25 years old). Alterations of metabolite levels of control sub-
jects were considered significant when exceeding two standard deviations.
RESULTS: There were parallel decreases of N-acetylaspartate (21%–82%) and reductions
of axonal density (44%–74%) in demyelinating plaques. Concomitant increases of choline
(75%–152%) and myo-inositol (84%–160%) corresponded to glial proliferation. Elevated lac-
tate was associated with inflammation.
CONCLUSION: The present data suggest that in vivo MRS indicates key pathologic features
of demyelinating lesions.
Multiple sclerosis (MS) is a chronic inflammatory
disease of the CNS characterized by focal areas of
demyelination (1, 2). The mechanisms behind the
destruction of myelin, however, are still poorly un-
derstood. Recent studies on oligodendrocyte pa-
thology suggest a heterogeneous pathogenesis (3).
The diagnosis of MS is generally made on the basis
of clinical, laboratory, and radiologic findings. MR
imaging, complemented by enhancement with the
contrast agent gadolinium-diethylene-triamine pen-
taacetic acid (Gd-DTPA) is the method of choice
for defining the location, extent, and activity of MS
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lesions in the brain (4, 5). MR imaging is often
implemented in therapeutic studies to define the re-
duction of disease activity during therapy. MR find-
ings, however, may be nonspecific and do not nec-
essarily allow definition of the underlying
pathologic changes within a single lesion. For ex-
ample, Gd-DTPA enhancement may also occur in
chronic inactive lesions, and hyperintense T2 le-
sions may indicate inflammation as well as demy-
elination or axonal loss (6).
Proton MR spectroscopy (MRS) has emerged as
a sensitive tool for studying the biochemical be-
havior of demyelinating plaques in vivo (5). Rela-
tive to normal-appearing white matter, metabolic
alterations detected by proton MRS include reduc-
tions of N-acetylaspartate (NAA) as a putative in-
dicator of persistant axonal damage, namely in
chronic MS lesions (7–9). Moreover, choline-con-
taining compounds (Cho) and myo-inositol (Ins)
were both found to be elevated within MS plaques,
suggesting enhanced membrane turnover (9–13).
The rise of lactate (Lac) within some lesions may
correspond to the degree of inflammation, ie, the
infiltration of macrophages in the acute episodes as
seen also in other cerebral diseases (12, 14).
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Table 1: Synopsis of clinical and diagnostic findings.
Patient #1 #2 #3
Age/years 20 37 21
Sex Female Male Female
Clinical findings at onset Bilateral optic neuritis, slight limb
ataxia, nausea, vomiting
Hemiparesis, hypesthesia of tri-
geminal nerve
Hemiparesis, focal seizures, mild
aphasia
CSF findings Normal OCB Increased total protein
Interval from first symptoms
to biopsy
2 months 7 months 7.5 months
MRI at biopsy Bilateral large lesions, Gd1 Large parietal lesion, multiple
periventricular lesions, partly
Gd1
Bilateral large lesions, Gd1
Follow-up clinical data For 6 years no further bout, no
disability other than vision loss
At least 1 further bout, rapid pro-
gression of disability
Several bouts, severely disabled
Poser criteria (20) Clinically probable MS Laboratory-supported definite MS Clinically definite MS
Disease course Monophasic (so far) Secondary progressive Secondary progressive
So far, few studies have investigated the utility
of proton MRS findings in morphologically con-
firmed demyelinating lesions. In fact, pertinent in-
vestigations have measured biopsy specimens (9,
12, 15, 16) or autopsy tissue from MS patients (17)
in an attempt to confirm the demyelinating process
rather than to relate MRS findings to detailed his-
topathologic and immunopathologic parameters of
the plaques. Because such data are critical for the
interpretation of MRS-based in vivo disease, the
present study compares in vivo MRS findings to
pathologic characteristics of lesions in three cases
of inflammatory CNS demyelination consistent
with MS, which were confirmed by biopsy.
Methods
Clinical History of Patients
This study includes three young adult patients who had been
subjected to brain biopsy because of equivocal diagnostic find-
ings that did not exclude certain treatable diseases other than
MS such as lymphoma, glioma, or toxoplasmosis. The three
patients were not selected on the basis of different types of
disease or from a larger group of patients. The clinical history,
CSF data, and MR findings were reported previously (18, 19)
and are summarized in Table 1. Between four and seven ster-
eotactic needle biopsies were taken from the left parieto-oc-
cipital white matter (case 1), right parietal white matter (case
2), and right frontoparietal white matter (case 3). Currently,
the diagnosis of MS is clinically definite in two patients ac-
cording to the Poser criteria (20). In one patient (case 1), how-
ever, MS is still only probable considering the lack of a second
bout during the past 6 years. No patient received steroids or
any immunosuppressive treatment prior to biopsy. All patients
were prescribed a course of steroids after biopsy, which ended
at least 2 weeks before MRS for cases 2 and 3, whereas case
1 still received 35 mg/d prednisolone at the time of the MRS
examination. Time elapsed between biopsy and subsequent
MRS examination of the patients was 6 weeks in case 1, 11
and 17 weeks in case 2, and 21 weeks in case 3.
Neuropathologic Analysis
Paraffin-embedded biopsy material, which had been collect-
ed at the Department of Neuropathology of the Georg-August
University at Go¨ttingen, was used. Sections were stained with
hematoxilin and eosin (H&E), Luxol fast blue (LFB), periodic
acid-Schiff (PAS), and Bielschowsky’s silver impregnation.
Immunocytochemical Analysis
Immunocytochemical analysis was performed with a biotin-
avidin or an alkaline phosphatase/anti-alkaline phosphatase
technique. The following primary antibodies were used (see
reference 19 and 21).
Myelin/oligodendrocytes.—Anti-myelin basic protein (MBP,
Boehringer Mannheim, Mannheim, Germany), anti-proteolipid
protein (PLP), and anti-myelin oligodendrocyte glycoprotein
(MOG) were used. The latter was provided by Dr. Piddlesden
(University of Cardiff, UK).
Monocytes/macrophages.—Anti-Ki-MlP was provided by
Dr. Radzun (University of Go¨ttingen, Germany). We also used
anti-27E10, anti-MRP14, anti-25F9, and anti-MRP8 (BMA
Biomedicals, August, Switzerland).
T cells.—Anti-CD3, (Dako, Denmark) was used.
Astrocytes.—Anti-glial fibrillary acid protein (GFAP)
(Dako, Denmark) was used.
Immunoglobulins.—Anti-human IgG (Dako, Denmark) was
used.
In Situ Hybridization
For in situ hybridization, digoxigenin-labeled riboprobes
specific for PLP mRNA were used (22). The source and spec-
ificity of the probes, the labeling techniques, and the methods
of in situ hybridization have been described in detail (23).
Axonal Density, Gliosis, Edema, and Blood Brain–Barrier
Breakdown
Axonal density was determined in sections stained with
Bielschowsky’s silver impregnation by point sampling using a
24-point Zeiss eyepiece (24). Measurements of all lesions were
performed at an identical final magnification of 3800 to guar-
antee comparability. Random points were superimposed on the
plaques and the periplaque white matter. The number of points
crossing axons was measured as a fraction of the total number
of points on the stereologic grid. A recent study confirmed the
reliability of this method for quantifying axonal density in dif-
ferent regions of the cerebral white matter (24). Axonal density
is expressed as the percentage of reduction compared with the
periplaque white matter (Fig 1A–C).
Gliosis was determined in sections stained for GFAP. Pro-
toplasmic gliosis with large swollen astrocytes was distin-
guished from fibrillary gliosis with dense glial scarring (Fig
1D–E). Blood brain–barrier (BBB) breakdown was assessed in
sections stained for human IgG. Moderate or severe protein
extravasation was distinguished. The degree of extracellular
edema (moderate or severe) was defined as the widening of
the extracellular space within the lesions. Severe edema re-
sulted in the formation of a vacuolated extracellular space. Gli-
AJNR: 20, October 1999 INFLAMMATORY CNS DEMYELINATION 1621
FIG 1. Bielschowsky’s silver impregnation shows axonal density in the normal periplaque white matter (patient 1) (A), a reduction by
45% (patient 3) (B), and a reduction by 75% (patient 1) (C) within the plaques (magnification for all, 3166). Prominent protoplasmic
gliosis with large astrocytes (D) is seen by immunocytochemistry for GFAP (patient 1). Numerous GFAP-positive cell processes (E)
indicate fibrillary gliosis (patient 3). Immunocytochemistry for MOG (F) shows an early active demyelinating lesion (patient 2). Macro-
phages carry MOG-positive degradation products in their cytoplasm. Dense macrophage infiltrate (G) is seen in the same lesion as
shown in F (immunocytochemistry for Ki-MlP).
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Table 2: Lesion histopathology and corresponding proton MRS-detected metabolic alterations. Absolute metabolite levels (mM/L VOI)
derived from proton MR spectra (STEAM, TR/TE/TM 5 3000/20/30 ms) of biopsied lesions of patients #1 to #3.
Patient #1 #2 #3 #1–3
Lesional activity ERM/LRM EA/LA DM NAWM
Axonal damage
Axon reduction*
NAA [mM]
(6.5 6 0.7 mM)‡
Relative NAA§
Edema¶
263%
1.2
2.4\
263/282%\
1
244%
5.1
221%
11
274%
2.9
255%
1
0
6.1–9.4
2
Astrocyte proliferation
Gliosis
Cho [mM]
(1.2 6 0.2 mM)‡
Relative Cho§
Ins [mM]
(2.5 6 0.6 mM)‡
Relative Ins§
Protoplasmatic/fibrillary
3.0
2.4\
1100/150%\
6.2
5.2\
1108/148%\
Protoplasmatic
2.4
1100%
4.6
184%
Fibrillary
3.1
1152%
6.5
1160%
2
0.5
2.7
5.8
Inflammation
Macrophages/mm2
Macrophage activation¶
Lac [mM]
(#0.5 mM)‡
688
2
4.7
3.0\
1316
1
4.9
1084
2
2.5
8–100
2
0.5
* Percentage reduction/increase in comparison to periplaque white matter. ‡ controls (n 5 20; white matter, VOI 5 12 ml, mean 6 SD);
§ Percentage changes in comparison to normal controls; ¶ 1 5 moderate; 11 5 severe; 2 5 none; \ Values correspond to a large/small VOI of
the same lesion. VOI’s for spectroscopy range from 4.1–8.0 ml. EA 5 early active lesion; LA 5 late active lesion; DM 5 demyelinated lesion;
ERM 5 early remyelinating lesion; LRM 5 late remyelinating lesion; NAWM 5 normal appearing white matter.
osis, BBB breakdown, and extracellular edema were deter-
mined at the same final magnification.
Morphometric Analysis
The number of oligodendrocytes (MOG immunocytochem-
istry or PLP mRNA in situ hybridization), T cells (CD3 im-
munocytochemistry), and macrophages (KiM1P immunocyto-
chemistry) stained per square unit of tissue was determined on
serial sections selected according to the demyelinating activity
within the plaques (see Results). The number of cells was de-
termined in at least 10 standardized microscopic fields of
10,000 mm2 each that were defined by an ocular morphometric
grid. The values are summarized in Table 2 as the number of
cells per mm2.
MR Spectroscopy
Combined MR/MRS studies were performed on a 2-T im-
aging unit (Magnetom SP4000, Siemens Erlangen, Germany)
using the standard imaging head coil. Image-guided selection
of a volume of interest (VOI) for proton MRS was based on
T1-weighted fast-low-angle-shot images. Short-echo-time pro-
ton MR spectra (3000/20/30 [TR/TE/TM], 128 accumulations)
were acquired using a single-voxel stimulated-echo acquisi-
tion-mode localization sequence as described previously (25).
VOIs were placed to include lesions, defined as areas of Tl-
weighted signal decrease, as well as unsuspicious white matter
in small paraventricular locations to allow for intrasubject
comparisons. ‘‘Gray matter’’ spectra were obtained from VOIs
placed symmetrically around the sagittal fissure.
Data evaluation comprised a correction of the spectroscopic
time-domain data for residual eddy current effects and calibra-
tion of signal intensities in proportion to the actual coil loading
to account for intersubject sensitivity differences. For display
purposes only, spectral postprocessing involved zero-filling to
4 K complex data points (2048 ms), Gaussian filtering (half-
width 317 ms), and manual-phase correction. Absolute metab-
olite levels were obtained with LCModel, a user-independent
fitting routine based on a library of model spectra of all indi-
vidual metabolites (26–28). Concentration values are expressed
as mmol/L VOI (mM) and are not corrected for contributions
by CSF and a small reduction of the numerical values by re-
sidual T1 and T2 relaxation effects.
Metabolite control values were obtained from a group of
age-matched healthy volunteers (n 5 40; age range, 20–35
years) investigated at the time of the patient measurements
with the same methodology. Apart from different T1 relaxation
weightings, the results were in general agreement with a more
recent study of young subjects performed in this laboratory
(28). Alterations of metabolite levels from those of control
subjects were considered significant when exceeding two stan-
dard deviations.
Results
Neuropathologic Findings
A total of 15 serial stereotactic needle biopsy
specimens (four to seven per patient) from different
plaque areas were available. All specimens con-
tained demyelinated tissue in various stages of de-
myelinating activity as well as areas of remyeli-
nation. A total of 18 lesions in different stages of
demyelinating activity were studied as defined be-
low. Additionally, four areas of periplaque white
matter were analyzed. Histologic characteristics of
MS plaques included inflammation and a certain
degree of either fibrillary or protoplasmic astrocytic
gliosis (Fig 1D–E), which were both present in all
samples. Oligodendrocytes were largely preserved
within the lesions and exhibited only a minor re-
duction compared with the periplaque white matter.
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FIG 2. T1-weighted gradient-echo MR images (3D fast low-angle shot, 4-mm partitions, 15/6 TR/TE, 208 flip angle) of patient 1 indicating
VOIs selected for MRS.
A, Transverse section with VOIs centered at the left parieto-occipital lesion (20 3 20 3 20 mm3) and in a contralateral control region
(16 3 30 3 16 mm3).
B, Sagittal section with a smaller VOI (16 3 16 3 16 mm3) encompassing the same lesion (note small defect in the skull and
corresponding biopsy canal),
C, Coronal section depicting an ipsilateral VOI (20 3 20 3 20 mm3) in left frontoparietal cortex unsuspicious at MR imaging.
Demyelinated plaques were infiltrated by numerous
macrophages (Fig 1G). Macrophage activation was
defined by the expression of MRP14 and 27E10
and was detected in actively demyelinating lesions.
Axonal density was more reduced in all lesions
than it was in periplaque white matter (Fig 1A–C).
Edema was present in all lesions but not in the
periplaque white matter. There was no systematic
relationship between the degree of edema and ax-
onal density.
Definition of Demyelinating Activity
According to the presence of myelin degradation
products in the macrophage cytoplasm and the ex-
pression of macrophage activation antigens (19,21),
the following stages of demyelinating activity were
distinguished.
Early active lesions.—Early active lesions (pa-
tient 2 [n54]) were located at the border between
demyelinated plaques and periplaque white matter.
Macrophages contained myelin degradation prod-
ucts that were stained with LFB and were immu-
noreactive for all myelin proteins, including MOG
(Fig 1F). The macrophages expressed the acute
stage inflammatory macrophage markers MRP14
and 27E10.
Late active lesions.—Myelin degradation (pa-
tient 2 [n53]) was more advanced in late active
lesions. Macrophages diffusely infiltrated the lesion
and contained myelin degradation products with
immunoreactivity for the major myelin proteins
MBP or PLP but not for MOG. Macrophages still
expressed the acute stage inflammatory marker
27E10.
Inactive demyelinated lesions.—These lesions
(patient 3 [n54]) were infiltrated by macrophages,
which contained either empty vacuoles or PAS-
positive degradation products and expressed the
chronic-stage inflammatory macrophage marker
25F9.
Early remyelinating lesions.—Early remyelinat-
ed lesions (patient 3 [n51]) were infiltrated by nu-
merous lymphocytes and macrophages and showed
clusters of axons surrounded by thin myelin
sheaths.
Late remyelinating lesions.—Only few macro-
phages were present in these lesions (shadow
plaques, patient 1 [n53]). The axons were sur-
rounded by thin myelin sheaths, and fibrillary gli-
osis was prominent.
Proton MRS Findings
As a typical example, Figure 2 shows selective
T1-weighted MR sections for patient 1 to indicate
the location and size of the VOIs chosen for MRS.
They demonstrate the demarcation of the demye-
linating disease (Gd-DTPA enhancement on MR
images 12 days before biopsy) by signal decreases.
The corresponding proton MR spectra in Figure 3
display the prominent single resonances of NAA,
creatine and phosphocreatine (Cr), choline-contain-
ing compounds, the coupled resonances for Ins and
Lac, and unresolved resonances from unassigned
methyl (0.8–0.9 ppm) and methylene (1.2–1.3
ppm) groups.
Table 2 summarizes the absolute metabolite lev-
els for all three patients derived from proton MRS
in vivo as well as mean white matter values for a
group of age-matched control subjects. In particu-
lar, for the small VOI of the biopsied lesion in case
1, proton MRS revealed a greater than fivefold re-
duction of NAA (1.2 versus 6.5 mM), a greater
than twofold increase of both Cho (3.0 versus 1.2
mM) and Ins (6.2 vs. 2.5 mM), and a marked in-
crease of Lac (4.7 mM). All changes clearly ex-
ceeded two standard deviations of control values.
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FIG 3. Localized proton MR spectra (stimulated-echo acquisi-
tion mode, 3000/20/30 [TR/TE/TM]) of patient 1 from locations
indicated in Figure 2. Left occipitoparietal lesion (top) image us-
ing a 4-mL VOI and (second row) 8-mL VOI, an ipsilateral 8-mL
VOI in unsuspicious left frontoparietal cortex (third row), and con-
tralateral control (bottom). Major resonances are due to N-ace-
tylaspartate (NAA), creatine and phosphocreatine (Cr), choline-
containing compounds (Cho), myo-inositol (Ins), and lactate
(Lac). Spectra are normalized for comparison.
In this case, a larger VOI (double size) also was
investigated to demonstrate the extent to which the
partial voluming of visible lesion and surrounding
normal-appearing white matter affects the mea-
sured metabolite concentrations. That is, the abso-
lute NAA decreased, and the Cho and Ins increase
appeared less marked with increasing partial vol-
uming. By volumetric assessment, normal-appear-
ing white matter contributed only below 10% for
the smaller VOI and up to 20% for the larger VOI
of this case. As seen on the images, the defect
caused by the biopsy canals also contributed to the
VOIs (up to 15%). Similar to CSF spaces, however,
this led to an equal decrease of all metabolites,
which ultimately did not affect the relative metab-
olite pattern. Similar considerations with a similar
magnitude of partial volume effects apply for the
VOIs chosen in cases 2 and 3. Similar findings
were obtained when the metabolic alterations in the
lesion were compared to values obtained in contra-
lateral white matter or ipsilateral frontoparietal
white matter. Both regions appeared normal at MR,
and the MRS-detected metabolite levels were with-
in normal ranges.
The lesion of case 2 (frontal part) showed only
a slight reduction of NAA (5.1 versus 6.5 mM),
but again a twofold increase of Cho and Ins, and a
markedly increased Lac (4.9 mM). An MRS fol-
low-up 6 weeks later revealed a decreased Lac lev-
el (2.8 mM), but only subtle changes for the other
metabolites within the limits of experimental un-
certainty. Nevertheless, the trend toward normal
Lac levels would comply with a recovery process
that includes an abatement of inflammation. In this
patient, normal-appearing white matter in two con-
tralateral locations also was affected by increases
of Cho (1.6–1.7 versus 1.2 mM), Ins (4.4–5.8 ver-
sus 2.5 mM), and Cr (5.2–5.7 versus 3.8 mM).
Compared with healthy volunteers, this indicates an
increase of 33% to 42% (Cho), 76% to 132% (Ins),
and 37% to 50% (Cr).
In case 3, the biopsied lesion showed a twofold
decrease of NAA and elevated Lac (2.5 mM). Pa-
tient 3 had the highest Cho and Ins levels of the
three patients studied, reaching 152% (Cho) and
160% (Ins) of the levels found in control subjects.
No significant changes were found in the midline
parietal gray matter matter of MS patients com-
pared with control subjects. Nevertheless, there was
a trend toward slightly increased levels of Cho. To-
tal Cr levels within lesions showed no statistically
significant deviations from control subjects; ie, 3.8
6 0.5 mM for white matter.
Correlation of Neuropathologic Results and MR
Spectra
Enumeration of axons revealed a substantial ax-
onal loss in all MS lesions compared with perip-
laque white matter. Correspondingly, there was a
decrease of NAA levels within the lesions as de-
termined by MRS (Table 2). In case 1, NAA levels
decreased by 63% to 82% (depending on VOI size)
as compared with histopathologic reduction of the
axonal density by 63% (compared with periplaque
white matter). Similarly, in cases 2 and 3, NAA
decreases of 21% and 55% corresponded to a re-
duction of axonal density by 44% and 74%, re-
spectively. No NAA reduction was found in nor-
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mal-appearing white matter. All MRS examinations
of biopsied lesions exhibited marked increases of
the absolute Cho (75%–152%) and Ins (84%–
160%) levels (Table 2). The most pronounced in-
creases occurred in demyelinating lesions with pre-
dominant fibrillary gliosis (patient 3). With
protoplasmic gliosis becoming more prominent in
remyelinating (patient 1) and active demyelinating
(patient 2) lesions, Cho and Ins levels were found
less elevated. Lac elevations of up to 4.9 mM, com-
pared with a maximal level of 0.5 mM in control
subjects, were identified in MS lesions (Table 2).
The highest Lac levels were found in lesions with
high inflammatory activity rather than in inactive
demyelinated plaques, with only a few infiltrating
mononuclear cells. In contrast, total Cr levels
showed no statistically significant deviations from
control subjects in the lesions investigated. In the
normal-appearing white matter of patient 2, which
was affected by glial abnormalities as evidenced by
marked increases of Cho and Ins, the Cr levels also
were increased beyond normal.
Discussion
A central finding of this study is the relationship
between the MRS-detected decrease of NAA in MS
lesions and the relative axonal density in Biel-
schowsky’s silver stains of corresponding biopsy
specimens. Notwithstanding uncertainties in match-
ing the actual sample volumes selected for MRS
and biopsies, as well as the influence of edema,
these results must be taken as strong support for
the interpretation of the NAA level as an indicator
of the degree of neuroaxonal integrity. Additional
findings include increased Cho and Ins levels that
may correspond to glial cell proliferation and ele-
vated Lac, which was most prominent in the most
active stages of inflammatory demyelination.
Each of the three patients investigated suffered
from inflammatory demyelination as revealed by
pathologic analysis. The initial clinical course and
MR findings were not typical for multiple sclerosis,
which was the reason for brain biopsy. Two of
three patients developed a relapsing-remitting
course and the diagnosis of multiple sclerosis be-
came clinically definite (3). One patient has re-
mained in a stable condition for 7 years and there-
fore does not fulfill the criteria of definite multiple
sclerosis. Nevertheless, beyond the more or less
typical clinical syndrome, the variability of demy-
elinating lesions as revealed by histopathologic
analysis and spectroscopy may be even more im-
portant. Recent immunopathologic studies clearly
showed heterogeneity in the pathologic structure of
actively demyelinating plaques, suggesting that dif-
ferent mechanisms of demyelination may occur in
different MS patients, independent of clinical
course. When multiple lesions from a single patient
were analyzed, very uniform patterns of inflam-
mation, demyelination, oligodendrocyte disease,
axonal loss, and remyelination were found. A high
variability of lesional structure, however, was ob-
served among different MS patients (3). This may
indicate that the findings from the cases presented
herein should be useful as a baseline for further
studies on the pathologic behavior of MS lesions
as revealed by MRS.
It is generally accepted that there is axonal dam-
age or transection and subsequent neuronal loss in
MS plaques (29, 30). These findings are supported
by previous MRS investigations describing NAA
reductions as a main feature of demyelinating and
neurometabolic disease (14). Other MRS studies of
MS biopsies or autopsies also reported NAA losses
but did not relate these findings quantitatively to
the axonal density within the plaques (9, 12, 15,
17). Because NAA appears to be a measure of neu-
roaxonal damage, it is an important predictor of
neuronal dysfunction and shows a strong correla-
tion with the patient’s disability (9, 31). A persis-
tent NAA decrease associated with no recovery of
clinical symptoms may indicate irreversible axonal
damage (8). Beyond reduced NAA levels within
MS plaques, NAA decreases of 10% to 20% have
also been claimed for normal-appearing white mat-
ter (12, 32). In our patients, no such alterations
were observed relative to data obtained from con-
trol subjects, indicating the presence of intact axons
within the normal-appearing white matter.
In contrast to NAA, levels of Cho were markedly
increased in all lesions. This increase was more
pronounced in inactive lesions with fibrillary glio-
sis than in active demyelinating lesions that re-
vealed protoplasmic gliosis. In cell culture, choline-
containing compounds were preferentially located
in oligodendrocytes and astrocytes (33). Their in-
crease in cerebral pathologic processes observed in
vivo has been associated with increased membrane
turnover, eg, in glial proliferation (14, 34). Major
components of the Cho resonance are choline-con-
taining compounds with small molecular weight,
such as phosphocholine and glycerophosphocho-
line (35), that form a pool involved in membrane
synthesis and degradation. In contrast to phospha-
tidylcholine, such components have sufficiently
long relaxation times to be detected under the pres-
ent experimental conditions (36). Most authors re-
port an early Cho increase in MS lesions or an el-
evated Cho/Cr ratio or both that may or may not
return to normal during subsequent months (9, 12,
32, 37). A study of experimental allergic enceph-
alomyelitis in guinea pigs attributed increases in
Cho/Cr to inflammatory infiltration alone and
found no significant contribution by demyelination
upon histologic study (38). Hence, the increase in
Cho would originate exclusively from an import of
choline oxidase within infiltrated macrophages and
lymphocytes into the lesion. Herein, the observa-
tion of marked Cho increases in connection with
fibrillary gliosis suggests that the formation of fi-
brillary glial processes may be a major factor of
Cho elevation in MS. Because, however, Cho was
also increased during active demyelination and re-
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myelination, in which fibrillary gliosis is much less
prominent, these observations suggest the impor-
tance of at least two different processes during MS
plaque evolution: inflammatory cellular infiltration
as well as increased membrane turnover associated
with fibrillary gliosis and possibly demyelination.
In agreement with recent proton MRS and MR
studies revealing metabolic but no morphologic al-
terations of normal-appearing white matter in pa-
tients with MS (39, 40), one of our patients (case
2) revealed strong increases of Cho, Ins, and Cr in
the contralateral white matter, indicating pro-
nounced gliosis. Because no NAA decrease was
found, and consistent with the observation of ele-
vated Cr that was present in both glial and neuronal
cells, glial proliferation seemed to precede neu-
roaxonal damage and MR-detectable lesion evolu-
tion. Of note, as the disease progressed, this patient
developed contralateral lesions that were apparent
with Gd-DTPA enhancement during MR imaging.
Similar to Cho, Ins levels were increased in all
lesion types and displayed higher levels in fibrillary
than in protoplasmic gliosis. According to proton
MRS studies of cell cultures, Ins originates almost
exclusively from glial cells (41). Other studies re-
lated elevated Ins to the acute stage of active my-
elin breakdown (9, 13, 15, 42). We, however, found
it elevated also in inactive demyelinated lesions
without evidence of myelin phagocytosis. Consis-
tent with previous MRS studies of brain disorders
and, in particular, with common and opposing al-
terations of Cho and Ins levels in demyelinating
and hypomyelinating diseases (14, 43), the present
findings of elevated Ins most likely represent both
the accumulation of myelin breakdown products
during acute phases and astrocytosis in demyelin-
ated and remyelinated lesions. This also applies to
abnormal Ins levels in normal-appearing white
matter (case 2).
Although Cr levels within biopsied lesions were
normal compared with controls, they were in-
creased in the normal-appearing white matter of pa-
tient 2, which was affected by glial abnormalities
as evidenced by concomitant increases of Cho and
Ins. This finding is in line with investigations of
metabolite ratios measured by proton MR spectro-
scopic imaging that report an increase of Cr in and
around T1 hypointensities in relapsing-remitting
MS (39, 44). It may best be understood as a higher
density of cells per spectroscopic VOI that results
from glial proliferation in the presence of still-in-
tact neuroaxonal structures. In fact, both neuronal
and glial cells harbor Cr compounds for their cel-
lular homeostasis and energy needs. Further sup-
port for this interpretation stems from the fact that
we made similar observations of elevated Cho
(58%), Ins (112%), and Cr (58%) in one lesion
with normal NAA that was not biopsied in case 2.
Thus, the finding of more or less normal Cr levels
in MS lesions may be an ‘‘artifact’’ resulting from
counterbalancing effects of neuroaxonal loss and
glial proliferation.
The large lesions studied herein also displayed
notable Lac elevations that were identified by
chemical shift and the typical coupling constant of
7 Hz. Because the dominant bioenergetic pathway
in activated macrophages has been shown to be
glycolysis (45), this finding would indicate an in-
flammatory process with cellular infiltration, as
noted by others (12). Histologic findings of acti-
vated macrophages in lesions with highest Lac lev-
els are consistent with this view. Lac generation
after biopsy injury, however, might be considered,
but this should involve inactive lesions to a similar
extent. Because of neuronal mitochondrial injury,
increased glycolysis may be another source of Lac
(16).
The occurrence of broad resonances in the ali-
phatic methyl and methylene region in proton MR
spectra of MS plaques is often ascribed to the pres-
ence of mobile lipids, (eg, compare the top [lesion]
and bottom spectra [control subject] [Fig 3].). Al-
though minor contributions from very short-chain
fatty acids cannot entirely be excluded, the spectral
structure of these resonances hints at the prevalence
of mobile methyl and methylene residues from cy-
tosolic proteins. It is likely that such proteins as
well as cholesterol (;0.9 ppm) become elevated
either as a result of cellular disruption or during the
course of cellular proliferation and growth.
In conclusion, the comparison of biochemical
findings by quantitative proton MRS, with histo-
logic features of biopsy material in three cases of
demyelinating disease, demonstrate that in vivo as-
sessments provide parallel as well as complemen-
tary information as to the histopathologic and
pathophysiologic features of a single MS lesion.
Pertinent data help to guide the interpretation of
spectroscopic findings in terms of the cellular com-
position and metabolism within MS plaques.
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